Nkarta, Inc. (NKTX) Stock Price & Analysis
Nkarta, Inc. (NKTX) fell 1.30% to USD 2.27 as of July 25, 2026 at 03:41 UTC, according to Nexqual real-time market data.
NKTX last closed at USD 2.3; the session ranged USD 2.23–2.36 on volume of 691,577 shares. Market capitalization is $162.41M, with a 52-week range of USD 1.7–3.72 (NMS). Source: Nexqual, July 25, 2026 at 03:41 UTC.
Key Statistics (as of July 25, 2026 at 03:41 UTC)
| Price | USD 2.27 |
|---|---|
| Change | ▼ 1.30% (down) |
| Previous Close | USD 2.3 |
| Open | USD 2.32 |
| Day Range | USD 2.23 – 2.36 |
| 52-Week Range | USD 1.7 – 3.72 |
| Volume | 691,577 shares |
| Market Cap | $162.41M |
| Exchange | NMS |
Technical Analysis (NKTX)
Nexqual's technical model rates NKTX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:41 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.27 (neutral) |
| vs SMA50 | Below (USD 2.83) |
| MACD | -0.14 (negative) |
Analyst Ratings (NKTX)
Wall Street analysts rate NKTX "None" based on 6 analysts, with a mean price target of USD 11.33 (range USD 9–16), per Nexqual as of July 25, 2026 at 03:41 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 11.33 |
| High Target | USD 16 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (NKTX)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.36 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.37 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.29 vs est -0.3 ▲ beat |
| 2025-06-30 | USD -0.31 vs est -0.35 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financials & Fundamentals (NKTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -30.07% |
| Debt / Equity | 26.24 |
| Current Ratio | 12.96 |
| Total Cash | $230.43M |
| Total Debt | $75.00M |
| Free Cash Flow | $-57.38M |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financial Health Score (NKTX)
Nexqual rates Nkarta, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:41 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $230M cash vs $75M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$87M |
| Efficiency | Critical — ROE -30%, ROA -17.1% |
Ownership (NKTX)
| Insider Ownership | +4.88% |
|---|---|
| Institutional Ownership | +81.12% |
| Shares Outstanding | 71.55M |
| Float | 60.44M |
| Short % of Float | +5.91% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Leadership (NKTX)
Nkarta, Inc. is led by Paul J. Hastings (age 65), CEO & Director, per Nexqual as of July 25, 2026 at 03:41 UTC.
| CEO & Director | Paul J. Hastings (age 65) |
|---|---|
| President and Principal Accounting & Financial Officer | Nadir Mahmood (age 45) |
Major Backers & Investors (NKTX)
Notable institutional backers of Nkarta, Inc. include RA Capital Management, L.P., NEA Management Company, LLC, Samsara BioCapital, LLC, according to Nexqual as of July 25, 2026 at 03:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 15.1% |
| NEA Management Company, LLC | 4.99% |
| Samsara BioCapital, LLC | 4.9% |
| SR One Capital Management, LP | 4.66% |
| GSK plc | 4.4% |
| Monaco Asset Management SAM | 3.52% |
| Alyeska Investment Group, L.p. | 2.91% |
| Two Sigma Investments, LP | 2.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.51% |
| Vanguard Group | 5.86% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
From Nkarta, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary NK cell engineering platform is based on a modular and generalizable approach that we believe enables us to generate next generation and new product candidates in a rapid and cost-efficient manner.
- Below are the five core technologies that comprise our proprietary platform.
- We have developed proprietary technologies designed to generate an abundant supply of NK cells, increase NK cell recognition of target antigens, and enhance NK cell fitness to support scalable, off the shelf administration.
- Continue to progress our proprietary manufacturing capabilities to enable speed, control, flexibility, scalability, and cost efficiency.
Partnerships
- Composition-of-matter claims relating to our NKSTIM cells are estimated to have expired in Q4 2024, subject to any patent term adjustments or extensions. 15   In August 2016, we entered into a license agreement with the Licensors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | USD 2.03 | ▲ 0.5% |
| PLRX | Pliant Therapeutics, Inc. | USD 1.09 | ▼ 0.91% |
| CCCC | C4 Therapeutics, Inc. | USD 3.4 | ▼ 9.09% |
| BDTX | Black Diamond Therapeutics, Inc | USD 1.76 | ▼ 3.83% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 10.07 | ▼ 8.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:41 UTC. This page is informational and not investment advice.